Phoenix Technology Group Expands Customer Success and Ophthalmic Training Team

Jonathan Hawes, 20-year tech veteran joins to lead Customer Success; Denise Armiger former Leica/Bioptigen and Heidelberg clinical trainer joins growing clinical specialist team

 

Pleasanton, CA, USA, – Today, Phoenix Technology Group (Phoenix), a leading provider of advanced ophthalmic imaging solutions, announces the addition of Jonathan Hawes to the new position of Senior Director, Customer Success and Denise Armiger CRA, OCT-C, as Global Clinical Trainer.  The addition of Hawes and Armiger add critical skills and capabilities to support the growing global adoption of Phoenix ophthalmic imaging products.

 

Hawes comes to Phoenix with over 20 years of experience in customer success, complex program management, operations and business development in the technology and imaging sectors.  He has led and implemented global deployment and support programs for hardware, software and software-as-a-service products, including complex imaging systems. Hawes will lead the newly formed Phoenix Customer Success team, implementing processes for delivery, training and customer service across the company’s Phoenix ICON™ and Phoenix MICRON™ retinal imaging platforms, and Phoenix CONNECT™ telemedicine platform for remote ROP (Retinopathy of Prematurity) screening.

 

Armiger comes to Phoenix from Leica, where she was a Global Clinical Training and Marketing Manager for the Bioptigen optical coherence tomography (OCT) product line.  Prior to Leica, Armiger was with Heidelberg as a Senior Applications Specialist, and Emory Eye Center as an ophthalmic photographer.  In total, she has nearly 20 years of experience in ophthalmic imaging, as well as extensive experience training on the use of medical imaging platforms in the operating room and neonatal intensive care unit (NICU). Armiger’s experience and abilities expand our existing world-class ophthalmic photographer training team.

 

“We are thrilled to have Jonathan and Denise on board at Phoenix,” said J. Scott Carr, chairman and CEO of Phoenix.  “Phoenix continues to experience rapid customer adoption of our imaging and telemedicine solutions.  We are committed to exceeding our customers’ expectations.  Jonathan’s proven experience driving measurable customer success and Denise’s experience in both clinical and research imaging applications helps us ensure our customers will enjoy outstanding experiences with our products and service.”

 

About Phoenix Technology Group:  Phoenix Technology Group™ empowers people to see: we empower researchers to see more in their fight to prevent blindness; we empower clinicians to see more in their fight to save sight.  We do that by providing clinicians and researchers around the world with stunning retinal images, coupled with timely and accurate data about the retina and the eye. Founded by Bert Massie, Ph.D., inventor of the first digital camera for pediatric retinal imaging, our company created the Phoenix MICRON™ platform for in-vivo imaging of animals in eye research.  Phoenix MICRON™ is the standard of excellence for researchers worldwide: ten of the top twelve research institutions employ a Phoenix MICRON™ solution. In 2017, the company launched to great acclaim the Phoenix ICON™ platform which reinvented wide-field retinal imaging for human clinical applications. Phoenix ICON™ delivers stunning high-contrast, high-resolution images, with quality you can see and data you can trust. The Phoenix ICON™ platform also boasts a number of features including a lighter weight cart and a six-hour battery life.  Recognizing that telemedicine is the future of ROP screening, in 2018, Phoenix launched Phoenix CONNECT, which today is the most widely adopted telemedicine platform for ROP screening. Phoenix CONNECT connects the nursing, ophthalmology, and neonatology teams to enable delivery of the best care by facilitating timely expert screening to babies in any NICU. And, the platform implements a proven screening workflow that generates critical photo documentation to enhance treatment determination and reduce risk.

 

 

Contact: Jen King, Phoenix Technology Group, ph.1.925.485.1100 x 244, jen.king@phoenixtech.com